LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Author Correction

    Nasser K. Altorki / Zachary H. Walsh / Johannes C. Melms / Jeffery L. Port / Benjamin E. Lee / Abu Nasar / Cathy Spinelli / Lindsay Caprio / Meri Rogava / Patricia Ho / Paul J. Christos / Ashish Saxena / Olivier Elemento / Bhavneet Bhinder / Casey Ager / Amit Dipak Amin / Nicholas J. Sanfilippo / Vivek Mittal / Alain C. Borczuk /
    Silvia C. Formenti / Benjamin Izar / Timothy E. McGraw

    Nature Communications, Vol 15, Iss 1, Pp 1-

    Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

    2024  Volume 1

    Keywords Science ; Q
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer

    Nasser K. Altorki / Zachary H. Walsh / Johannes C. Melms / Jeffery L. Port / Benjamin E. Lee / Abu Nasar / Cathy Spinelli / Lindsay Caprio / Meri Rogava / Patricia Ho / Paul J. Christos / Ashish Saxena / Olivier Elemento / Bhavneet Bhinder / Casey Ager / Amit Dipak Amin / Nicholas J. Sanfilippo / Vivek Mittal / Alain C. Borczuk /
    Silvia C. Formenti / Benjamin Izar / Timothy E. McGraw

    Nature Communications, Vol 14, Iss 1, Pp 1-

    survival outcomes and molecular correlates of a randomized phase II trial

    2023  Volume 14

    Abstract: Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or ... ...

    Abstract Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation (DRT). The trial met its primary endpoint of major pathological response, which was significantly higher following DRT with no new safety signals. Here, we report on the prespecified secondary endpoint of disease-free survival (DFS) regardless of treatment assignment and the prespecified exploratory analysis of DFS in each arm of the trial. DFS at 2 and 3 years across patients in both arms of the trial were 73% (95% CI: 62.1–84.5) and 65% (95% CI: 52.5–76.9) respectively. For the exploratory endpoint of DFS in each arm of the trial, three-year DFS was 63% (95% CI: 46.0–80.4) in the durvalumab monotherapy arm compared to 67% (95% CI: 49.6–83.4) in the dual therapy arm. In addition, we report post hoc exploratory analysis of progression-free survival as well as molecular correlates of response and recurrence through high-plex immunophenotyping of sequentially collected peripheral blood and gene expression profiles from resected tumors in both treatment arms. Together, our results contribute to the evolving landscape of neoadjuvant treatment regimens for NSCLC and identify easily measurable potential biomarkers of response and recurrence.
    Keywords Science ; Q
    Subject code 610
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top